Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.0K | $-11.44M | $-0.25 |
| 2024 | $181.0K | $-9.54M | $-0.25 |
| 2023 | $0.00 | $-8.89M | $-0.31 |
| 2022 | $134.0K | $-13.07M | $-0.45 |
| 2021 | $571.0K | $-12.19M | $-0.47 |
Social Signal Score
Earnings
Fri, Nov 13(in 3 months)
Consensus estimate $-0.08 per share
Typical surprise +22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.14 vs $-0.08miss
- Fri, May 8$-0.07 vs $-0.08beat
- Fri, Mar 27$-0.07 vs $-0.09beat
- Fri, Nov 14$-0.07 vs $-0.09beat
- Fri, Aug 8$-0.06 vs $-0.11beat
- Fri, May 9$-0.06 vs $-0.07beat
Estimates and results for ENTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ENTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·2d ago·Negative
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a discussion hosted by Canaccord Genuity.
View source ↗